Unknown

Dataset Information

0

Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease.


ABSTRACT: To date, we still lack disease-modifying therapies for Alzheimer's disease (AD). Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD. Five patients with mild to moderate AD received oral benfotiamine (300 mg daily) over 18 months. All patients were examined by positron emission tomography with Pittsburgh compound B (PiB-PET) and exhibited positive imaging with ?-amyloid deposition, and three received PiB-PET imaging at follow-up. The five patients exhibited cognitive improvement as assayed by the Mini-Mental Status Examination (MMSE) with an average increase of 3.2 points at month 18 of benfotiamine administration. The three patients who received follow-up PiB-PET had a 36.7% increase in the average standardized uptake value ratio in the brain compared with that in the first scan. Importantly, the MMSE scores of these three had an average increase of 3 points during the same period. Benfotiamine significantly improved the cognitive abilities of mild to moderate AD patients independently of brain amyloid accumulation. Our study provides new insight to the development of disease-modifying therapy.

SUBMITTER: Pan X 

PROVIDER: S-EPMC5567484 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease.

Pan Xiaoli X   Chen Zhichun Z   Fei Guoqiang G   Pan Shumei S   Bao Weiqi W   Ren Shuhua S   Guan Yihui Y   Zhong Chunjiu C  

Neuroscience bulletin 20161001 6


To date, we still lack disease-modifying therapies for Alzheimer's disease (AD). Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD. Five patients with mild to moderate AD received oral benfotiamine (300 mg daily) over 18 months. All patients were examined by positron emission tomography with Pittsburgh compound B (PiB-PET) and exhibited positive imaging with β-amyloid deposition, and three received PiB-PET imaging at follow-up. The f  ...[more]

Similar Datasets

| S-EPMC2211476 | biostudies-literature
| S-EPMC7880246 | biostudies-literature
| S-EPMC5679465 | biostudies-literature
2024-07-01 | GSE214417 | GEO
| S-EPMC5549157 | biostudies-other
| S-EPMC11342302 | biostudies-literature
| S-EPMC8340838 | biostudies-literature
2024-07-01 | GSE214406 | GEO
2024-07-01 | GSE212972 | GEO
2024-07-01 | GSE214416 | GEO